QS Pharma provides a broad range of contract research services
for pharmaceutical and biopharmaceutical companies worldwide.
The business is founded on the tenet of Quality with Speed™
and is based on the founders' strategic expertise and knowledge
in the broadly defined area of pharmaceutical product development.
The focus of QS Pharma spans the development process from
the screening and identification of New Chemical Entities
(NCEs) through the development of stable, bioavailable, manufacturable,
and registerable dosage forms for use in clinical trials and
regulatory submissions.
QS Pharma formulation development capabilities encompass the
full range of delivery options including parenteral and oral.
Analytical capabilities of QS Pharma range from the transfer
and qualification of an existing method to complete methods
development and validation for drug substance, toxicology
formulations drug product and cleaning verification. cGMP
manufacturing capabilities are available for clinical supplies
of NCEs and blinding of comparators. QS Pharma offers ICH
stability condition storage and analytical testing for drug
substance and drug product.
QS Pharma is a fully owned subsidiary
of WIL Research Holding Company, Inc., New York, and the other
member companies of the corporation are:
